A multiplatform metabolomic approach to the basis of antimonial action and resistance in Leishmania infantum

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Rojo, David ^a   Canuto, Gisele A B ^a,b   Castilho Martins, Emerson A ^a,c   Tavares, Marina F M ^b   Barbas, Coral ^a   López Gonzálvez, Ángeles ^a   Rivas, Luis ^d  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF AMAPÁ   (Brazil)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY TARTRATE; ARGININE; CITRULLINE; ORNITHINE; PUTRESCINE; TRYPANOTHIONE; TRYPANOTHIONE DISULFIDE; UNCLASSIFIED DRUG; ANTIMONY; ANTIPROTOZOAL AGENT;

AMINO ACID METABOLISM; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETOXIFICATION; DRUG RESISTANCE; GLYCOLYSIS; IC50; IN VITRO STUDY; LEISHMANIA INFANTUM; LEISHMANICIDAL ACTIVITY; MICROBIAL GROWTH; MORTALITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROMASTIGOTE; DRUG EFFECTS; HUMAN; LEISHMANIASIS, VISCERAL; LIQUID CHROMATOGRAPHY; METABOLISM; METABOLOME; METABOLOMICS; PARASITOLOGY; PROCEDURES; TANDEM MASS SPECTROMETRY;

ANTIMONY; ANTIPROTOZOAL AGENTS; CHROMATOGRAPHY, LIQUID; DRUG RESISTANCE; HUMANS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; METABOLOME; METABOLOMICS; TANDEM MASS SPECTROMETRY;

EID: 84940481145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130675     Document Type: Article

References (69)

1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. (2012) Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS One 7: E35671. doi: 10.1371/journal.pone.0035671 PMID: 22693548
2. Sundar S (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849-854. PMID: 11703838
3. Solano-Gallego L, Miro G, Koutinas A, Cardoso L, Pennisi MG, Ferrer L, et al. (2011) LeishVet guidelines for the practical management of canine leishmaniosis. Parasit Vectors 4: 86. doi: 10.1186/1756-3305-4-86 PMID: 21599936
4. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA (2009) Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev: CD004834.
5. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M (2010) Combination therapy for visceral leishmaniasis. The Lancet infectious diseases 10: 184-194. doi: 10.1016/S1473-3099(10) 70011-6 PMID: 20185097
6. Choudhury K, Zander D, Kube M, Reinhardt R, Clos J (2008) Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. Int J Parasitol 38: 1411-1423. doi: 10.1016/j.ijpara. 2008.03.005 PMID: 18457839
7. Kumar D, Kulshrestha A, Singh R, Salotra P (2009) In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: Correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53: 835-838. doi: 10.1128/AAC.01233-08 PMID: 19015344
8. Moreira DS, Monte Neto RL, Andrade JM, Santi AM, Reis PG, Frézard F, et al. (2013) Molecular characterization of the MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony. Int J Parasitol Drugs Drug Resist 3: 143-153. doi: 10.1016/j.ijpddr.2013. 08.001 PMID: 24533304
9. Seblova V, Oury B, Eddaikra N, Ait-Oudhia K, Pratlong F, Gazanion E, et al. (2014) Transmission potential of antimony-resistant leishmania field isolates. Antimicrob Agents Chemother 58: 6273-6276. doi: 10.1128/AAC.02406-13 PMID: 25049256
10. Mukherjee B, Mukhopadhyay R, Bannerjee B, Chowdhury S, Mukherjee S, Naskar K, et al. (2013) Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc Natl Acad Sci U S A 110: E575-582. doi: 10.1073/pnas. 1213839110 PMID: 23341611
11. Vanaerschot M, Huijben S, Van den Broeck F, Dujardin JC (2014) Drug resistance in vectorborne parasites: Multiple actors and scenarios for an evolutionary arms race. FEMS Microbiol Rev 38: 41-55. doi: 10.1111/1574-6976.12032 PMID: 23815683
12. Ashutosh, Sundar S, Goyal N (2007) Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56: 143-153. PMID: 17244793
13. Wyllie S, Cunningham ML, Fairlamb AH (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279: 39925-39932. PMID: 15252045
14. Guimond C, Trudel N, Brochu C, Marquis N, El Fadili A, Peytavi R, et al. (2003) Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res 31: 5886-5896. PMID: 14530437
15. Haimeur A, Guimond C, Pilote S, Mukhopadhyay R, Rosen BP, Poulin R, et al. (1999) Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol 34: 726-735. PMID: 10564512
16. Ashutosh, Garg M, Sundar S, Duncan R, Nakhasi HL, Goyal N (2012) Downregulation of mitogen-Activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance. Antimicrob Agents Chemother 56: 518-525. doi: 10.1128/AAC.00736-11 PMID: 22064540
17. Brotherton MC, Bourassa S, Leprohon P, Legare D, Poirier GG, Droit A, et al. (2013) Proteomic and genomic analyses of antimony resistant Leishmania infantum mutant. PLoS One 8: E81899. doi: 10. 1371/journal.pone.0081899 PMID: 24312377
18. Das S, Shah P, Baharia RK, Tandon R, Khare P, Sundar S, et al. (2013) Over-expression of 60s ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of Leishmania donovani. PLoS Negl Trop Dis 7: E2527. doi: 10.1371/journal.pntd.0002527 PMID: 24340105
19. Biyani N, Singh AK, Mandal S, Chawla B, Madhubala R (2011) Differential expression of proteins in antimony-susceptible and-resistant isolates of Leishmania donovani. Mol Biochem Parasitol 179: 91-99. doi: 10.1016/j.molbiopara.2011.06.004 PMID: 21736901
20. Kumar A, Sisodia B, Misra P, Sundar S, Shasany AK, Dube A (2010) Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol 70: 609-617. doi: 10.1111/j.1365-2125.2010. 03716.x PMID: 20840452
21. Zhou Y, Messier N, Ouellette M, Rosen BP, Mukhopadhyay R (2004) Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J Biol Chem 279: 37445-37451. PMID: 15220340
22. Fyfe PK, Westrop GD, Silva AM, Coombs GH, Hunter WN (2012) Leishmania TDR1 structure, a unique trimeric glutathione transferase capable of deglutathionylation and antimonial prodrug activation. Proc Natl Acad Sci U S A 109: 11693-11698. doi: 10.1073/pnas.1202593109 PMID: 22753509
23. Marquis N, Gourbal B, Rosen BP, Mukhopadhyay R, Ouellette M (2005) Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol 57: 1690-1699. PMID: 16135234
24. Gomez MA, Navas A, Marquez R, Rojas LJ, Vargas DA, Blanco VM, et al. (2014) Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: Impact on intracellular parasite survival. J Antimicrob Chemother 69: 139-149. doi: 10.1093/jac/dkt334 PMID: 23975742
25. Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, Chatterjee M (2010) Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol 173: 162-164. doi: 10.1016/j.molbiopara.2010.05.015 PMID: 20553768
26. Wyllie S, Vickers TJ, Fairlamb AH (2008) Roles of trypanothione S-Transferase and tryparedoxin peroxidase in resistance to antimonials. Antimicrob Agents Chemother 52: 1359-1365. doi: 10.1128/AAC. 01563-07 PMID: 18250189
27. Muniz-Junqueira MI, de Paula-Coelho VN (2008) Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-Alpha production, but only via TNF-Alpha it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro. Int Immunopharmacol 8: 1633-1638. doi: 10.1016/j.intimp.2008.07.011 PMID: 18692597
28. Pathak MK, Yi T (2001) Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 167: 3391-3397. PMID: 11544330
29. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. (2008) The relationship between leishmaniasis and AIDS: The second 10 years. Clin Microbiol Rev 21: 334-359, table of contents. doi: 10.1128/CMR.00061-07 PMID: 18400800
30. Perry MR, Wyllie S, Raab A, Feldmann J, Fairlamb AH (2013) Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis. Proc Natl Acad Sci U S A 110: 19932-19937. doi: 10.1073/pnas.1311535110 PMID: 24167266
31. Downing T, Stark O, Vanaerschot M, Imamura H, Sanders M, et al. (2012) Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. Infect Genet Evol 12: 149-159. doi: 10.1016/j.meegid.2011.11.005 PMID: 22119748
32. Singh N, Almeida R, Kothari H, Kumar P, Mandal G, Chatterjee M, et al. (2007) Differential gene expression analysis in antimony-unresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray. Parasitology 134: 777-787. PMID: 17306059
33. Vanaerschot M, Decuypere S, Downing T, Imamura H, Stark O, De Doncker S, et al. (2012) Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. J Infect Dis 206: 752-755. doi: 10.1093/infdis/jis424 PMID: 22753945
34. El Fadili K, Drummelsmith J, Roy G, Jardim A, Ouellette M (2009) Down regulation of KMP-11 in Leishmania infantum axenic antimony resistant amastigotes as revealed by a proteomic screen. Exp Parasitol 123: 51-57. doi: 10.1016/j.exppara.2009.05.013 PMID: 19500579
35. Matrangolo FS, Liarte DB, Andrade LC, de Melo MF, Andrade JM, Ferreira RF, et al. (2013) Comparative proteomic analysis of antimony-resistant and-susceptible Leishmania braziliensis and Leishmania infantum chagasi lines. Mol Biochem Parasitol 190: 63-75. doi: 10.1016/j.molbiopara.2013.06.006 PMID: 23831370
36. Walker J, Gongora R, Vasquez JJ, Drummelsmith J, Burchmore R, Roy G, et al. (2012) Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol Biochem Parasitol 183: 166-176. doi: 10.1016/j.molbiopara.2012.03.002 PMID: 22449941
37. Vincent IM, Weidt S, Rivas L, Burgess K, Smith TK, Ouellette M (2014) Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism. Int J Parasitol Drugs Drug Resist 4: 20-27. doi: 10.1016/j.ijpddr.2013.11.002 PMID: 24596665
38. t'Kindt R, Scheltema RA, Jankevics A, Brunker K, Rijal S, Dujardin JC, et al. (2010) Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Negl Trop Dis 4: E904. doi: 10.1371/journal.pntd.0000904 PMID: 21152055
39. Scheltema RA, Decuypere S, T'Kindt R, Dujardin JC, Coombs GH, Breitling R (2010) The potential of metabolomics for Leishmania research in the post-genomics era. Parasitology 137: 1291-1302. doi: 10.1017/S0031182009992022 PMID: 20109253
40. Canuto GA, Castilho-Martins EA, Tavares M, Lopez-Gonzalvez A, Rivas L, Barbas C (2012) CE-ESIMS metabolic fingerprinting of Leishmania resistance to antimony treatment. Electrophoresis 33: 1901-1910. doi: 10.1002/elps.201200007 PMID: 22740478
41. Berg M, Mannaert A, Vanaerschot M, Van Der Auwera G, Dujardin JC (2013) (Post-) Genomic approaches to tackle drug resistance in Leishmania. Parasitology 140: 1492-1505. doi: 10.1017/S0031182013000140 PMID: 23480865
42. Requena JM (2012) Lights and shadows on gene organization and regulation of gene expression in Leishmania. Front Biosci 17: 2069-2085.
43. De Gaudenzi JG, Noe G, Campo VA, Frasch AC, Cassola A (2011) Gene expression regulation in trypanosomatids. Essays Biochem 51: 31-46. doi: 10.1042/bse0510031 PMID: 22023440
44. Vincent IM, Barrett MP (2015) Metabolomic-Based Strategies for Anti-Parasite Drug Discovery. J Biomol Screen 20: 44-55. doi: 10.1177/1087057114551519 PMID: 25281738
45. Gika HG, Macpherson E, Theodoridis GA, Wilson ID (2008) Evaluation of the repeatability of ultra-performance liquid chromatography-TOF-MS for global metabolic profiling of human urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 871: 299-305. doi: 10.1016/j.jchromb.2008.05.048 PMID: 18579458
46. Mehta A, Shaha C (2006) Mechanism of metalloid-induced death in Leishmania spp.: Role of iron, reactive oxygen species, Ca2+, and glutathione. Free Radic Biol Med 40: 1857-1868. PMID: 16678023
47. Flohe L (2012) The trypanothione system and its implications in the therapy of trypanosomatid diseases. Int J Med Microbiol 302: 216-220. doi: 10.1016/j.ijmm.2012.07.008 PMID: 22889611
48. Manta B, Comini M, Medeiros A, Hugo M, Trujillo M, Radi R (2013) Trypanothione: A unique bis-glutathionyl derivative in trypanosomatids. Biochim Biophys Acta 1830: 3199-3216. doi: 10.1016/j. bbagen.2013.01.013 PMID: 23396001
49. Krauth-Siegel RL, Leroux AE (2012) Low-molecular-mass antioxidants in parasites. Antioxid Redox Signal 17: 583-607. doi: 10.1089/ars.2011.4392 PMID: 22053812
50. Castilho-Martins EA, Laranjeira da Silva MF, dos Santos MG, Muxel SM, Floeter-Winter LM (2011) Axenic Leishmania amazonensis promastigotes sense both the external and internal arginine pool distinctly regulating the two transporter-coding genes. PLoS One 6: E27818. doi: 10.1371/journal.pone. 0027818 PMID: 22114701
51. Rai S, Bhaskar, Goel SK, Nath Dwivedi U, Sundar S, Goyal N (2013) Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani. PLoS One 8: E74862. doi: 10. 1371/journal.pone.0074862 PMID: 24069359
52. Tielens AG, Van Hellemond JJ (1998) Differences in energy metabolism between trypanosomatidae. Parasitol Today 14: 265-272. PMID: 17040781
53. Saunders EC, Ng WW, Kloehn J, Chambers JM, Ng M, McConville MJ (2014) Induction of a stringent metabolic response in intracellular stages of Leishmania mexicana leads to increased dependence on mitochondrial metabolism. PLoS Pathog 10: E1003888. doi: 10.1371/journal.ppat.1003888 PMID: 24465208
54. Hart DT, Coombs GH (1982) Leishmania mexicana: Energy metabolism of amastigotes and promastigotes. Exp Parasitol 54: 397-409. PMID: 7151947
55. Sudhandiran G, Shaha C (2003) Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J Biol Chem 278: 25120-25132. PMID: 12707265
56. Manzano JI, Carvalho L, Perez-Victoria JM, Castanys S, Gamarro F (2011) Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major. Antimicrob Agents Chemother 55: 1045-1052. doi: 10.1128/AAC.01545-10 PMID: 21199921
57. Maugeri DA, Cazzulo JJ, Burchmore RJ, Barrett MP, Ogbunude PO (2003) Pentose phosphate metabolism in Leishmania mexicana. Mol Biochem Parasitol 130: 117-125. PMID: 12946848
58. Boitz JM, Ullman B, Jardim A, Carter NS (2012) Purine salvage in Leishmania: Complex or simple by design? Trends Parasitol 28: 345-352. doi: 10.1016/j.pt.2012.05.005 PMID: 22726696
59. Carter NS, Yates P, Arendt CS, Boitz JM, Ullman B (2008) Purine and pyrimidine metabolism in Leishmania. Adv Exp Med Biol 625: 141-154. doi: 10.1007/978-0-387-77570-8-12 PMID: 18365665
60. Ginger ML, Chance ML, Sadler IH, Goad LJ (2001) The biosynthetic incorporation of the intact leucine skeleton into sterol by the trypanosomatid Leishmania mexicana. J Biol Chem 276: 11674-11682. PMID: 11148203
61. Zhang K, Bangs JD, Beverley SM (2010) Sphingolipids in parasitic protozoa. Adv Exp Med Biol 688: 238-248. PMID: 20919659
62. Novozhilova NM, Bovin NV (2010) Structure, functions, and biosynthesis of glycoconjugates of Leishmania spp. cell surface. Biochemistry (Mosc) 75: 686-694.
63. Brannigan JA, Smith BA, Yu Z, Brzozowski AM, Hodgkinson MR, Maroof A, et al. (2010) N-myristoyltransferase from Leishmania donovani: Structural and functional characterisation of a potential drug target for visceral leishmaniasis. J Mol Biol 396: 985-999. doi: 10.1016/j.jmb.2009.12.032 PMID: 20036251
64. Lefurgey A, Gannon M, Blum J, Ingram P (2005) Leishmania donovani amastigotes mobilize organic and inorganic osmolytes during regulatory volume decrease. J Eukaryot Microbiol 52: 277-289. PMID: 15927005
65. Berg M, Vanaerschot M, Jankevics A, Cuypers B, Maes I, Mukherjee S, et al. (2013) Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure. Mol Microbiol 90: 428-442. doi: 10.1111/mmi.12374 PMID: 24020363
66. Perez-Pertejo Y, Reguera RM, Ordonez D, Balana-Fouce R (2006) Characterization of a methionine adenosyltransferase over-expressing strain in the trypanosomatid Leishmania donovani. Biochim Biophys Acta 1760: 10-19. PMID: 16280200
67. Opperdoes FR, Michels PA (2008) The metabolic repertoire of Leishmania and implications for drug discovery. In: Myler PJ, Fasel N, editors. Leishmania: After The Genome Norfolk, U.K Caister Academic Press. pp. 123-158.
68. Williams RA, Westrop GD, Coombs GH (2009) Two pathways for cysteine biosynthesis in Leishmania major. Biochem J 420: 451-462. doi: 10.1042/BJ20082441 PMID: 19296828
69. Mina JG, Mosely JA, Ali HZ, Denny PW, Steel PG (2011) Exploring Leishmania major inositol phosphorylceramide synthase (LmjIPCS): Insights into the ceramide binding domain. Org Biomol Chem 9: 1823-1830. doi: 10.1039/c0ob00871k PMID: 21267500